Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
Clinical trial NCT02959554 · TERMINATED
Trial details
- NCT number
- NCT02959554
- Sponsor
- AIO-Studien-gGmbH
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2020-08-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.